♦  Sells $34.6 million of a $39 million Series C equity funding round from existing investors with the lead investment from MedCare Investment Funds.
♦  Presents two analyses of outcomes from a U.S. Feasibility Study of its investigational Imagio® breast imaging device at the annual meeting of the European Congress of Radiology 2014.
♦  Receives the CE Mark for Imagio® in Europe.
♦  Completes active enrollment of subjects in its U.S.-based PIONEER Pivotal Study of Imagio®. The study was designed to determine if this technology will provide information to the physician to determine if a woman may avoid negative biopsies. This information will serve as the basis for the company’s Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA).